Clinical Trials Logo

Clinical Trial Summary

This research study tests whether GLYX-13 - an experimental drug that acts on a brain receptor called NMDA - can decrease symptoms of OCD within hours. This is not a treatment study. Results from this study will allow doctors and researchers to better understand if you and others with OCD may respond to a class of medications that target the NMDA brain receptor.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02267629
Study type Interventional
Source New York State Psychiatric Institute
Contact
Status Completed
Phase Phase 2
Start date October 2014
Completion date February 2016

See also
  Status Clinical Trial Phase
Recruiting NCT01949753 - Influence of Pregnenolone on Exposure Therapy in Obsessive-compulsive Disorder Phase 2
Recruiting NCT04042038 - Neural Predictors and Neural Changes Associated With Cognitive Behavior Therapy for Obssesive Compulsive Disorder N/A
Completed NCT02867449 - Metacognitive Therapy for Obsessive-Compulsive Disorder N/A
Completed NCT01368510 - Intensive Cognitive-Behavioral Therapy For Obsessive-Compulsive Disorder N/A
Not yet recruiting NCT05422469 - OCD Biomarker Survey Employing sEEG and Stimulation: The OBSESS Trial N/A
Active, not recruiting NCT03300947 - Psilocybin for Treatment of Obsessive Compulsive Disorder Phase 1
Recruiting NCT02773082 - Reclaimâ„¢ Deep Brain Stimulation (DBS) Therapy for Obsessive-Compulsive Disorder (OCD) N/A
Not yet recruiting NCT06360991 - DBS for Treatment-resistant Obsessive-compulsive Disorder N/A
Completed NCT03605316 - Deep Electrical Neuromodulation in Obsessive-compulsive Disorder